AU2019358585B2 - Pharmaceutical compositions comprising RPL554 in HFA-134a for administration by inhalation - Google Patents

Pharmaceutical compositions comprising RPL554 in HFA-134a for administration by inhalation Download PDF

Info

Publication number
AU2019358585B2
AU2019358585B2 AU2019358585A AU2019358585A AU2019358585B2 AU 2019358585 B2 AU2019358585 B2 AU 2019358585B2 AU 2019358585 A AU2019358585 A AU 2019358585A AU 2019358585 A AU2019358585 A AU 2019358585A AU 2019358585 B2 AU2019358585 B2 AU 2019358585B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
rpl554
liquid pharmaceutical
particles
hfa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019358585A
Other languages
English (en)
Other versions
AU2019358585A1 (en
Inventor
Phillip A. Haywood
Peter Lionel Spargo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verona Pharma Ltd
Original Assignee
Verona Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verona Pharma Ltd filed Critical Verona Pharma Ltd
Publication of AU2019358585A1 publication Critical patent/AU2019358585A1/en
Application granted granted Critical
Publication of AU2019358585B2 publication Critical patent/AU2019358585B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2019358585A 2018-10-09 2019-10-09 Pharmaceutical compositions comprising RPL554 in HFA-134a for administration by inhalation Active AU2019358585B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816447.5 2018-10-09
GB1816447.5A GB2578093B (en) 2018-10-09 2018-10-09 Liquid pharmaceutical composition comprising RPL554 and HFA-134A
PCT/GB2019/052863 WO2020074894A1 (en) 2018-10-09 2019-10-09 Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation

Publications (2)

Publication Number Publication Date
AU2019358585A1 AU2019358585A1 (en) 2021-04-15
AU2019358585B2 true AU2019358585B2 (en) 2025-01-16

Family

ID=64394831

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019358585A Active AU2019358585B2 (en) 2018-10-09 2019-10-09 Pharmaceutical compositions comprising RPL554 in HFA-134a for administration by inhalation

Country Status (27)

Country Link
US (2) US20210379053A1 (enExample)
EP (2) EP3960157A1 (enExample)
JP (2) JP7578587B2 (enExample)
KR (1) KR20210073532A (enExample)
CN (1) CN112912064B (enExample)
AU (1) AU2019358585B2 (enExample)
BR (1) BR112021006712A2 (enExample)
CA (1) CA3113167A1 (enExample)
CY (1) CY1124943T1 (enExample)
DK (1) DK3820446T3 (enExample)
ES (1) ES2899744T3 (enExample)
GB (1) GB2578093B (enExample)
HR (1) HRP20220053T1 (enExample)
HU (1) HUE057780T2 (enExample)
IL (1) IL282032A (enExample)
LT (1) LT3820446T (enExample)
MX (2) MX2021003599A (enExample)
MY (1) MY207302A (enExample)
PH (1) PH12021550767A1 (enExample)
PL (1) PL3820446T3 (enExample)
PT (1) PT3820446T (enExample)
RS (1) RS62775B1 (enExample)
SG (1) SG11202102567UA (enExample)
SI (1) SI3820446T1 (enExample)
SM (1) SMT202200044T1 (enExample)
WO (1) WO2020074894A1 (enExample)
ZA (1) ZA202102039B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3231444T1 (sl) 2014-05-12 2020-04-30 Verona Pharma Plc Novo zdravljenje
GB201502260D0 (en) 2015-02-11 2015-04-01 Verona Pharma Plc Salt of Pyrimido[6,1-A]Isoquinolin-4-one compound
GB2594480A (en) * 2020-04-28 2021-11-03 Verona Pharma Plc New treatment
GB202202297D0 (en) 2022-02-21 2022-04-06 Verona Pharma Plc Formulation production process
JP2025534762A (ja) * 2022-10-28 2025-10-17 江蘇恒瑞医薬股▲ふん▼有限公司 イソキノリノン系化合物を含む医薬組成物及びその調製方法
EP4378942A1 (en) 2022-12-02 2024-06-05 Sandoz AG Crystal form of a pde3/4 inhibitor
TW202506117A (zh) 2023-06-26 2025-02-16 英商維羅納製藥Ｐｌｃ公司 顆粒組成物

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014140647A1 (en) * 2013-03-15 2014-09-18 Verona Pharma Plc Drug combination
WO2015173551A1 (en) * 2014-05-12 2015-11-19 Verona Pharma Plc New treatment
WO2016128742A1 (en) * 2015-02-11 2016-08-18 Verona Pharma Plc Salt of a pyrimido[6,1-a]isoquinolin-4-one compound

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165558B1 (en) 1999-03-31 2003-09-24 Vernalis Limited Derivatives of pyrimido[6,1-a]isoquinolin-4-one
PH12013500261A1 (en) * 2010-08-09 2013-03-04 Verona Pharma Plc Crystalline form of pyrimidio[6,1-a]isoquinolin-4-one compound
US10022303B2 (en) * 2012-02-28 2018-07-17 Iceutica Pty Ltd. Inhalable pharmaceutical compositions
DK3494962T3 (da) * 2014-09-15 2021-06-21 Verona Pharma Plc Flydende inhalationsformulering omfattende RPL554

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014140647A1 (en) * 2013-03-15 2014-09-18 Verona Pharma Plc Drug combination
WO2015173551A1 (en) * 2014-05-12 2015-11-19 Verona Pharma Plc New treatment
WO2016128742A1 (en) * 2015-02-11 2016-08-18 Verona Pharma Plc Salt of a pyrimido[6,1-a]isoquinolin-4-one compound

Also Published As

Publication number Publication date
CN112912064A (zh) 2021-06-04
LT3820446T (lt) 2021-12-10
KR20210073532A (ko) 2021-06-18
SG11202102567UA (en) 2021-04-29
GB201816447D0 (en) 2018-11-28
ES2899744T3 (es) 2022-03-14
MY207302A (en) 2025-02-15
DK3820446T3 (da) 2021-12-06
US20210379053A1 (en) 2021-12-09
JP2024113096A (ja) 2024-08-21
PH12021550767A1 (en) 2021-10-04
EP3960157A1 (en) 2022-03-02
EP3820446B1 (en) 2021-11-03
BR112021006712A2 (pt) 2021-07-27
WO2020074894A1 (en) 2020-04-16
MX2021003599A (es) 2021-05-28
GB2578093B (en) 2020-11-18
AU2019358585A1 (en) 2021-04-15
JP7578587B2 (ja) 2024-11-06
IL282032A (en) 2021-05-31
EP3820446A1 (en) 2021-05-19
SMT202200044T1 (it) 2022-05-12
JP2022513566A (ja) 2022-02-09
GB2578093A (en) 2020-04-22
CN112912064B (zh) 2025-02-14
PT3820446T (pt) 2021-12-03
PL3820446T3 (pl) 2022-03-14
MX2024001499A (es) 2024-02-27
RS62775B1 (sr) 2022-01-31
US20250049781A1 (en) 2025-02-13
CY1124943T1 (el) 2023-01-05
CA3113167A1 (en) 2020-04-16
SI3820446T1 (sl) 2022-01-31
ZA202102039B (en) 2022-08-31
HUE057780T2 (hu) 2022-06-28
HRP20220053T1 (hr) 2022-04-15

Similar Documents

Publication Publication Date Title
AU2019358585B2 (en) Pharmaceutical compositions comprising RPL554 in HFA-134a for administration by inhalation
EP2435024B1 (en) Compositions for respiratory delivery of active agents and associated methods and systems
EP1248597B1 (en) Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
US20060257324A1 (en) Pharmaceutical solution formulations for pressurised metered dose inhalers
CA2835927A1 (en) Compositions, methods & systems for respiratory delivery of two or more active agents
CN103998039A (zh) 包含噻托溴铵的可吸入药物
JP2007508283A (ja) カルボン酸界面活性剤を含むエアロゾル製剤
HUP0302036A2 (hu) Glükokortikoidot tartalmazó készítmény bronchopulmonális betegségek kezelésére
KR20120100901A (ko) 포모테롤 및 베클로메타손 디프로피오네이트의 약학적 에어로졸 제제
HK40061834A (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
RU2813959C2 (ru) Фармацевтические композиции, содержащие RPL554 в HFA-134A для введения посредством ингаляции
HK40042852A (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
HK40042852B (en) Pharmaceutical compositions comprising rpl554 in hfa-134a for administration by inhalation
US20090180969A1 (en) Pharmaceutical formulation comprising an anticholinergic drug
HK1169027B (en) Compositions for respiratory delivery of active agents and associated methods and systems
HK1169307B (en) Respiratory delivery of active agents
HK1228797B (en) Compositions for respiratory delivery of active agents and associated methods and systems
HK1228797A (en) Compositions for respiratory delivery of active agents and associated methods and systems
HK1228797A1 (en) Compositions for respiratory delivery of active agents and associated methods and systems

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)